Condition: Myelodysplastic Syndromes · Sponsor: Kyntra Bio
The study is designed to determine the efficacy and safety of roxadustat for the treatment of anemia due to very low, low, or intermediate risk MDS in participants with high transfusion burden (HTB).
This description comes directly from the study's public registry record.
Mairead Carney · 415-978-1337 · mcarney@kyntrabio.com
Javier Moreno · 415-978-1466 · jmoreno@kyntrabio.com
Always discuss trial participation with your own doctor first.
| Locations not yet listed on the registry record. |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07722988